Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Mesothelin-Targeted Antibody Drug Conjugate

Geo Regions

Mesothelin-Targeted Antibody Drug Conjugate

PF-08052666 | SGN-MesoC2 is an investigational compound. Its safety and efficacy have not been established.

Share to an HCP

Overview + Rationale

  • PF-08052666 (SGN-MesoC2) is an ADC that targets human mesothelin4
  • PF-08052666 (SGN-MesoC2) consists of an anti-MSLN mAb conjugated to SGD-12280 (a novel topoisomerase 1 inhibitor) by a cleavable methylsulfonylpyrimidine tripeptide linker4

 

RATIONAL FOR CANCER TARGET:

  • Mesothelin (MSLN) is a 40-kDa cell surface differentiation antigen present on normal mesothelial cells and plays a role in the regulation of cell proliferation, growth, and adhesion signaling1
  • Overexpression of mesothelin has been identified in many different tumor types (including lung and ovarian cancers) and in hematological malignancies such as acute myeloid leukemia2
  • It’s limited expression in normal tissues and overexpression in tumor tissues can result in reduced nonspecific toxicity, making MSLN an attractive target for oncology drug development3

Stage of Development

Other
Advanced Solid Tumors
Phase 1 Monotherapy and Combination
This information is current as of February 4th 2025.

ADC, antibody-drug conjugate; mAb, monoclonal antibody; MesoC2: mesothelin campothecin 2.

REFERENCES:  1. Hassan et al. Clin Cancer Res. 15 June 2004; 10 (12): 3937–3942; 2. Faust et al. Cancers 2022, 14, 1550; 3. Celbi C. Mol. Ther. Oncology. 31,100756, 2023; 4. Data on File. INVESTIGATOR’S BROCHURE. SGN-MesoC 2. Number: 02. 11-Mar-2024; 5.  Clinicaltrials.gov.  https://clinicaltrials.gov/study/NCT06466187.  Accessed January 16, 2025.